Transact - Transforming magnetic resonance spectroscopy into a clinical tool
From 01-03-2013 to 28-02-2017
Website: http://www.transact-itn.eu
Description
In vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging (MRS(I)) are unique, indispensable techniques for non-invasive metabolic imaging. Important areas where MRS(I) can make a difference are oncology and neurology, where metabolic changes due to, e.g., tumour formation, can be detected earlier and more sensitively than with morphological imaging modalities alone. Despite its huge proven potential, MRS(I) is not yet a routine clinical tool operated solely by clinicians. This requires reliable automation of complex procedures, strengthening standardisation and quality control. This in turn requires significant research progress and training of a new generation of scientists. Specifically, TRANSACT aims at: - Training 13 young scientists as future leaders in the field of MRS(I), capable of contributing with essential new developments such as spectral quality assurance criteria and standards, and optimal exploitation of complementarities between multi-modal magnetic resonance imaging modalities. - Pursuing research advances in theoretical and practical aspects of MRS, in particular experimental design by quantum mechanical simulation, data acquisition, data processing, data fusion and biomedical applications in oncology and neurology. - Establishing Europe as leader in the field within three sectors: academia, industry, clinic. TRANSACT links 10 academic and 4 industrial partners with complementary expertise in basic science, clinical research and information technology. Through a detailed training programme consisting of individual research projects, well-targeted
Team
- Diana Sima, Co-promoter
- Sabine Van Huffel, Promoter
Financing
Funding: EU Funding - European Funding
Program/Grant Type: MSCA ITN - Marie Sklodowska-Curie Actions International Training Networks
Events
2/09/2024:
PhD defense - Martijn Oldenhof
Machine Learning for Advanced Chemical Analysis and Structure Recognition in Drug Discovery
3/09/2024:
Meet the Jury Igor Tetko on Advanced Machine Learning in Drug Discovery
12/09/2024:
Multimodal analysis of cell-free DNA for sensitive cancer detection in low-coverage and low-sample settings
Seminar by Antoine Passemiers
News
STADIUS Alumni Herman Verrelst – new CEO of Biocartis
08 June 2017
Herman Verrelst, the founder of KU Leuven spin-off Cartagenia, who has been working in Silicon Valley, US for the last few years will be returning to Belgium to follow the steps of Rudi Pauwels as CEO of the Belgian diagnostic company, Biocartis.
Supporting healthcare policymaking via machine learning – batteries included!
29 May 2017
STADIUS takes the lead in the data analytics efforts in an ambitious European Project MIDAS.
Marc Claesen gives an interview about his PhD for the magazine of the Faculty of Engineering Sciences "Geniaal"
10 February 2017
Did you know that in Belgium approximately one third of type 2 diabetes patients are unaware of their condition?
Joos Vandewalle is nieuwe voorzitter KVAB
09 October 2016
Op 5 oktober 2016 heeft de Algemene Vergadering van de Academie KVAB Joos Vandewalle verkozen tot voorzitter van de KVAB.